Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 172

1.

Absence of CHEK2*1100delC mutation in families with hereditary breast cancer in North America.

Iniesta MD, Gorin MA, Chien LC, Thomas SM, Milliron KJ, Douglas JA, Merajver SD.

Cancer Genet Cytogenet. 2010 Oct 15;202(2):136-40. doi: 10.1016/j.cancergencyto.2010.07.124.

PMID:
20875877
2.

CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women.

Adank MA, Jonker MA, Kluijt I, van Mil SE, Oldenburg RA, Mooi WJ, Hogervorst FB, van den Ouweland AM, Gille JJ, Schmidt MK, van der Vaart AW, Meijers-Heijboer H, Waisfisz Q.

J Med Genet. 2011 Dec;48(12):860-3. doi: 10.1136/jmedgenet-2011-100380. Epub 2011 Nov 5.

PMID:
22058428
3.

Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.

Schutte M, Seal S, Barfoot R, Meijers-Heijboer H, Wasielewski M, Evans DG, Eccles D, Meijers C, Lohman F, Klijn J, van den Ouweland A, Futreal PA, Nathanson KL, Weber BL, Easton DF, Stratton MR, Rahman N; Breast Cancer Linkage Consortium..

Am J Hum Genet. 2003 Apr;72(4):1023-8. Epub 2003 Feb 27.

4.

The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.

Oldenburg RA, Kroeze-Jansema K, Kraan J, Morreau H, Klijn JG, Hoogerbrugge N, Ligtenberg MJ, van Asperen CJ, Vasen HF, Meijers C, Meijers-Heijboer H, de Bock TH, Cornelisse CJ, Devilee P.

Cancer Res. 2003 Dec 1;63(23):8153-7.

5.

Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases.

Adank MA, Verhoef S, Oldenburg RA, Schmidt MK, Hooning MJ, Martens JW, Broeks A, Rookus M, Waisfisz Q, Witte BI, Jonker MA, Meijers-Heijboer H.

Eur J Cancer. 2013 May;49(8):1993-9. doi: 10.1016/j.ejca.2013.01.009. Epub 2013 Feb 14.

PMID:
23415889
6.

German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer.

Rashid MU, Jakubowska A, Justenhoven C, Harth V, Pesch B, Baisch C, Pierl CB, Brüning T, Ko Y, Benner A, Wichmann HE, Brauch H, Hamann U; GENICA Network..

Eur J Cancer. 2005 Dec;41(18):2896-903. Epub 2005 Oct 18.

PMID:
16239104
7.

Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.

Laitman Y, Kaufman B, Lahad EL, Papa MZ, Friedman E.

Isr Med Assoc J. 2007 Nov;9(11):791-6.

8.

Frequency of the CHEK2 1100delC mutation among women with breast cancer: an international study.

Zhang S, Phelan CM, Zhang P, Rousseau F, Ghadirian P, Robidoux A, Foulkes W, Hamel N, McCready D, Trudeau M, Lynch H, Horsman D, De Matsuda ML, Aziz Z, Gomes M, Costa MM, Liede A, Poll A, Sun P, Narod SA.

Cancer Res. 2008 Apr 1;68(7):2154-7. doi: 10.1158/0008-5472.CAN-07-5187.

9.

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.

Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR; CHEK2-Breast Cancer Consortium..

Nat Genet. 2002 May;31(1):55-9. Epub 2002 Apr 22.

PMID:
11967536
10.

CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.

Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG.

J Clin Oncol. 2008 Feb 1;26(4):542-8. doi: 10.1200/JCO.2007.12.5922. Epub 2008 Jan 2. Review.

PMID:
18172190
11.
12.

Low frequency of the CHEK2*1100delC mutation among breast cancer probands from three regions of Poland.

Kwiatkowska E, Skasko E, Niwinska A, Wojciechowska-Lacka A, Rachtan J, Molong L, Nowakowska D, Konopka B, Janiec-Jankowska A, Paszko Z, Steffen J.

Neoplasma. 2006;53(4):305-8.

PMID:
16830057
13.

The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation.

Choi DH, Cho DY, Lee MH, Park HS, Ahn SH, Son BH, Haffty BG.

Breast Cancer Res Treat. 2008 Dec;112(3):569-73. doi: 10.1007/s10549-007-9878-z. Epub 2008 Jan 3.

PMID:
18175216
14.

[CHEK2 c.1100delC may not contribute to genetic background of hereditary breast cancer from Shanghai of China].

Song CG, Hu Z, Yuan WT, Di GH, Shen ZZ, Huang W, Shao ZM.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2006 Aug;23(4):443-5. Chinese.

PMID:
16883537
15.

CHEK2 1100delC and male breast cancer in the Netherlands.

Wasielewski M, den Bakker MA, van den Ouweland A, Meijer-van Gelder ME, Portengen H, Klijn JG, Meijers-Heijboer H, Foekens JA, Schutte M.

Breast Cancer Res Treat. 2009 Jul;116(2):397-400. doi: 10.1007/s10549-008-0162-7. Epub 2008 Aug 31.

PMID:
18759107
16.

The CHEK2 1100delC allelic variant is not present in familial and sporadic breast cancer cases from Moroccan population.

Marouf C, Hajji O, Diakité B, Tazzite A, Jouhadi H, Benider A, Nadifi S.

Springerplus. 2015 Feb 1;4:38. doi: 10.1186/s40064-014-0778-5. eCollection 2015.

17.

Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.

Schmidt MK, Tollenaar RA, de Kemp SR, Broeks A, Cornelisse CJ, Smit VT, Peterse JL, van Leeuwen FE, Van't Veer LJ.

J Clin Oncol. 2007 Jan 1;25(1):64-9. Epub 2006 Nov 28.

PMID:
17132695
18.
19.

CHEK2*1100delC does not contribute to risk to breast cancer among Malay, Chinese and Indians in Malaysia.

Thirthagiri E, Cheong LS, Yip CH, Teo SH.

Fam Cancer. 2009;8(4):355-8. doi: 10.1007/s10689-009-9244-x. Epub 2009 Apr 28.

PMID:
19399639
20.

CHEK2 1100delC is a susceptibility allele for HNPCC-related colorectal cancer.

Wasielewski M, Vasen H, Wijnen J, Hooning M, Dooijes D, Tops C, Klijn JG, Meijers-Heijboer H, Schutte M.

Clin Cancer Res. 2008 Aug 1;14(15):4989-94. doi: 10.1158/1078-0432.CCR-08-0389.

Supplemental Content

Support Center